Showing 11-20 of 574 results for "".
- ASA, Nicklaus Companies, and ahead Partner to Educate Golfers on Sun Safetyhttps://practicaldermatology.com/news/asa-nicklaus-companies-and-ahead-partner-to-educate-golfers-on-sun-safety/2461730/Nicklaus Companies and ahead, a provider of premium golf and leisure headwear, are joining forces with American Skin Association (ASA) to raise awareness about melanoma and educate golfers on the importance of sun safety. Both companies will use their social platforms to provide awareness and educ…
- Nielsen BioSciences, Maruho Co. Ltd. Enter License Agreement for the Treatment of Common Wartshttps://practicaldermatology.com/news/nielsen-biosciences-maruho-co-ltd-enter-license-agreement-for-the-treatment-of-common-warts/2461719/Nielsen BioSciences, Inc. has entered into a license agreement with Maruho Co., Ltd. granting Maruho exclusive rights to market Candin in Japan for the treatment of Verruca vulgaris. Candin is an approved diagnostic skin test and currently not approved by the U,S. Food and Drug Administration (FD…
- Metal Implants May Cause Nickel Hypersensitivityhttps://practicaldermatology.com/news/metal-implants-may-cause-nickel-hypersensitivity/2461614/Dermatologists are seeing more patients concerned about a possible skin hypersensitivity to the nickel or other metals used in implanted medical devices. Millions of people in the U.S. report having a metal allergy, and current estimates state that 10 percent of Americans will receive a medical im…
- Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiaryhttps://practicaldermatology.com/news/takeda-completes-acquisition-of-nimbus-tyk2-subsidiary/2461552/Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion. Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nimbus as NDI-034858. Wi…
- Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Study Causes of Atopic Dermatitis and Food Allergyhttps://practicaldermatology.com/news/mount-sinai-researchers-awarded-12-million-nih-grant-to-create-a-center-to-study-causes-of-atopic-dermatitis-and-food-allergy/2461520/Mount Sinai researchers have been awarded $12 million over 5 years by the National Institutes of Health (NIH) to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis, according to a news release. The Systems Biology of Early Atopy (SunBEAm…
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is published onlin…
- CHMP Recommends European Approval of Nivolumab/Relatimab for Certain Melanomashttps://practicaldermatology.com/news/chmp-recommends-european-approval-of-nivolumabrelatimab-for-certain-melanomas/2461278/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Bristol Myers Squibb’s fixed-dose combination of nivolumab and relatlimab for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adoles…
- Partner Therapeutics Moves Ahead with Phase 3 Study of Leukine Plus Ipilumimab and Nivolumab for Melanomahttps://practicaldermatology.com/news/partner-therapeutics-moves-ahead-with-phase-3-study-of-leukine-plus-ipilumimab-and-nivolumab-for-melanoma/2460524/Partner Therapeutics, Inc. is resuming enrollment in the National Cancer Institute (NCI)-sponsored ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) study of Leukine plus Ipilumimab and Nivolumab for Melanoma following a successful planned interim analysis. EA6141 (NCT02339571) is a randomized control…
- Researchers Explore Nitric Oxide to Slow Progression of COVID-19https://practicaldermatology.com/news/industry-responds-to-covid-19-researchers-call-for-exploration-of-nitric-oxide-to-slow-progression-of-covid-19/2460477/George Washington University (GW) researchers urge renewed research of nitric oxide treatment as a potential tool to fight SARS-CoV-2, the coronavirus that causes COVID-19, in a review published in the journal Nitric Oxide. The authors suggest that if nitric oxide's efficacy is illustrated for COVI…
- Mount Sinai Researcher Receives NIH Grant to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19https://practicaldermatology.com/news/mount-sinai-researcher-receives-nih-grant-to-study-immune-responses-of-patients-with-inflammatory-skin-diseases-in-the-setting-of-covid-19/2460458/Patients with moderate to severe atopic dermatitis who take a biologic treatment such as dupilumab seem to be protected from developing serious complications of COVID-19 and are also less likely to be hospitalized due to complications. Now, researchers from the Icahn School of Medicine at Mount Si…